When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARQT - Arcutis concludes patient enrollment in mid-stage study of ARQ-154 for psoriasis
Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics (ARQT-1.9%) has completed enrollment of Phase 2b trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for scalp psoriasis.
More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news,